A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) M16-438

Grants and Contracts Details

StatusFinished
Effective start/end date7/16/20 → 5/10/22

Funding

  • AbbVie Incorporated: $25,574.00